RT Journal Article
SR Electronic
T1 Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.01.20166413
DO 10.1101/2020.08.01.20166413
A1 Qin, Youwen
A1 Méric, Guillaume
A1 Long, Tao
A1 Watrous, Jeramie D.
A1 Burgess, Stephen
A1 Havulinna, Aki S.
A1 Ritchie, Scott C.
A1 Brożyńska, Marta
A1 Jousilahti, Pekka
A1 Perola, Markus
A1 Lahti, Leo
A1 Niiranen, Teemu
A1 Cheng, Susan
A1 Salomaa, Veikko
A1 Jain, Mohit
A1 Inouye, Michael
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.01.20166413.abstract
AB Bioactive metabolites are central to numerous pathways and disease pathophysiology, yet many bioactive metabolites are still uncharacterized. Here, we quantified bioactive metabolites using untargeted LC-MS plasma metabolomics in two large cohorts (combined N≈9,300) and utilized genome-wide association analysis and Mendelian randomization to uncover genetic loci with roles in bioactive metabolism and prioritize metabolite features for more in-depth characterization. We identified 118 loci associated with levels of 2,319 distinct metabolite features which replicated across cohorts and reached study-wide significance in meta-analysis. Of these loci, 39 were previously not known to be associated with blood metabolites. Loci harboring SLCO1B1 and UGT1A were highly pleiotropic, accounting for >40% of all associations. Two-sample Mendelian randomization found 46 causal effects of 31 metabolite features on at least one of five common diseases. Of these, 15, including leukotriene D4, had protective effects on both coronary heart disease and primary sclerosing cholangitis. We further assessed the association between baseline metabolite features and incident coronary heart disease using 16 years of follow-up health records. This study characterizes the genetic landscape of bioactive metabolite features and their putative causal effects on disease.Competing Interest StatementVS has received honoraria from Novo Nordisk and Sanofi for consultations. He also has ongoing research collaboration with Bayer Ltd (all unrelated to the present study).Funding StatementThe FINRISK02 cohort was mainly funded by budgetary funds of the Finnish Institute for Health and Welfare. Important additional funding has been obtained from the Finnish Academy and domestic non-profit foundations. SCR was funded by the UK National Institute for Health Research (NIHR) (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust). LL is supported by the Academy of Finland (grant no 295741). TN is supported by the Academy of Finland (grant no 321351), the Finnish Medical Foundation, the Paavo Nurmi Foundation, and the Emil Aaltonen Foundation. VS has been supported by the Finnish Foundation for Cardiovascular Research. MI was supported by the Munz Chair of Cardiovascular Prediction and Prevention. This study was supported by the Victorian Government Operational Infrastructure Support (OIS) program. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this manuscript are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The FINRISK 2002 survey has been approved by the Ethical Committee on Epidemiology and Public Health of the Helsinki and Uusimaa Hospital District (decision number 87/2001) and the participants have provided an informed consent. The study is conducted according to the World Medical Association Declaration of Helsinki on ethical principles. The FHS study data was accessed via dbGaP (approved study 2014.2023).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study is available with an approved study proposal via the THL Biobank (FINRISK) and NIH dbGaP (Framingham Heart Study).